Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Technical development and unallocated manufacturing by Year
Technical development and unallocated manufacturing R&D expenses ($M) ($M)
Moderna Technical development and unallocated manufacturing: $792M in FY2025, down 26.7% from a year earlier.
Latest, FY2025
792
Period ended Dec 31, 2025
Change on a year earlier
-26.7%
1,081 in FY2024
History
8 years
Since FY2018
Sources
5
Documents cited below
Where the FY2025 figure comes from
“Technical development and manufacturing expenses | 792 | 1,081 | 1,116”
Source: FY2025 10-K ↗
Reported in Form 10-K / 10-Q Item 7 (MD&A R&D Breakdown).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Technical development and unallocated manufacturing R&D expenses ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 792 | -26.7% | FY2025 10-K ↗ |
| FY2024 | Dec 31, 2024 | 1,081 | -3.1% | FY2025 10-K ↗ |
| FY2023 | Dec 31, 2023 | 1,116 | +56.5% | FY2025 10-K ↗ |
| FY2022 | Dec 31, 2022 | 713 | +159.3% | FY2024 10-K ↗ |
| FY2021 | Dec 31, 2021 | 275 | -1.4% | FY2023 10-K ↗ |
| FY2020 | Dec 31, 2020 | 279 | +228.2% | FY2021 10-K ↗ |
| FY2019 | Dec 31, 2019 | 85 | +2.3% | FY2021 10-K ↗ |
| FY2018 | Dec 31, 2018 | 83.1 | – | FY2020 10-K ↗ |
Cite this data
StockData. (2026). Moderna Technical development and unallocated manufacturing ($M), annual FY2018–FY2025 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/rd-tech-dev-mfg
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.